Skip to main content
OpenTrials
Completed

NCT Number: NCT01950416

Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis

This is a two-center, prospective, randomized, single-blind, investigator initiated, pharmacodynamic study of parallel design, carried out in 2 PCI-capable cardiology centers (Patras University Hospital and Konstantopoulio General Hospital of Athens).

Patients with ST elevation myocardial infarction, having undergone fibrinolysis in the previous 3 to 48 hours, who present high residual PR (defined as PRU ≥208 ) on admission, pre coronary angiography, will be randomized after written informed consent, in a 1:1 ratio to either:

Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD) starting 12±6 hours post LD, until discharge.

Or

Clopidogrel 600mg loading dose (LD), followed by a 150mg once daily maintenance dose (MD) starting 12±6 hours post LD, until discharge.

Platelet reactivity assessment will be performed at randomization (Hour 0) and at 2, 24 hours after randomization, as well as pre-discharge, using the VerifyNow assay, in platelet reactivity units (PRU).

Documentation of major adverse cardiac events (death, myocardial infarction, stroke, ischemia driven revascularization procedure with PCI or CABG) and bleeding (according to BARC criteria) will be performed until patient's discharge.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

ST Elevation Myocardial Infarction Cardiovascular Diseases Fibrinolysis Heart Diseases Infarction Ischemia Myocardial Infarction Myocardial Ischemia Necrosis P2Y12 Inhibitor Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Konstantopoulio General Hospital of Athens, Athens, Attica, Greece

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-85 years old
  • Patients with STEMI, having undergone fibrinolytic therapy in the previous 3 to 48 hours
  • Presenting HPR (≥208 PRU) post 300mg clopidogrel loading dose ( assessment immediately before coronary angiography)
  • Informed consent obtained in writing

Exclusion criteria

  • Pregnancy
  • Breastfeeding
  • Inability to give informed consent
  • Cardiogenic shock
  • Major periprocedural complications (death, stent thrombosis, vessel perforation, arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous antiarrhythmic agents, respiratory failure requiring intubation, vascular injury (arteriovenous shunt, retroperitoneal bleeding), major bleeding (need for bood transfusion or drop in haemoglobin post-PCI by ≥ 5 gr/ dl or intracranial bleeding)
  • Known hypersensitivity to ticagrelor or clopidogrel
  • History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 3 months.
  • Other bleeding diathesis, or considered by investigator to be at high risk for bleeding
  • Any previous history of stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).
  • Thombocytopenia (<100.000 / μL) at randomization
  • Anaemia (Hct <30%) at randomization
  • Polycytaemia (Hct > 52%) at randomization
  • Periprocedural IIb/IIIa inhibitors administration
  • Per os anticoagulants
  • Recent (< 6 weeks) major surgery or trauma, including GABG.
  • Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.
  • Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A inducers (rifampin /rifampicin, phenytoin, carbamazepine).
  • Increased risk of bradycardiac events.
  • Dialysis required.
  • Severe uncontrolled chronic obstructive pulmonary disease
  • Known severe hepatic impairement

Treatment and study plan

Ticagrelor 180mg loading dose and 90mg bid maintenance dose

Drug

Clopidogrel 600mg loading dose and 150mg maintenance dose

Drug

Primary outcomes

  1. Platelet reactivity at 2 hours post randomization between the 2 treatment arms

    Time frame: 2 hours

    Platelet reactivity at 2 hours post randomization between the 2 treatment arms

Secondary outcomes

  1. Platelet reactivity at 24 hours post randomization between the 2 treatment arms.

    Time frame: 24 hours

  2. Platelet reactivity pre-discharge between the 2 treatment arms

    Time frame: 5 days

  3. High on treatment platelet reactivity (HPR) rate (≥208 PRU) at 2 hours post randomization

    Time frame: 2 hours

  4. High on treatment platelet reactivity (HPR) rate (≥208 PRU) at 24 hours post randomization

    Time frame: 24 hours

  5. High on treatment platelet reactivity (HPR) rates (≥208 PRU) pre discharge

    Time frame: 5 days

Sponsors and collaborators

Lead sponsor

University of Patras

Other

Registry information

Official study title

Pharmacodynamic Assessment of Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Exhibiting High Platelet Reactivity Post Fibrinolysis

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Sep 25, 2013
Registry last updated
Aug 20, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.